1. Home
  2. NAMS vs NSP Comparison

NAMS vs NSP Comparison

Compare NAMS & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NAMS
  • NSP
  • Stock Information
  • Founded
  • NAMS 2019
  • NSP 1986
  • Country
  • NAMS Netherlands
  • NSP United States
  • Employees
  • NAMS N/A
  • NSP N/A
  • Industry
  • NAMS Biotechnology: Pharmaceutical Preparations
  • NSP Professional Services
  • Sector
  • NAMS Health Care
  • NSP Consumer Discretionary
  • Exchange
  • NAMS Nasdaq
  • NSP Nasdaq
  • Market Cap
  • NAMS 2.7B
  • NSP 2.9B
  • IPO Year
  • NAMS N/A
  • NSP 1997
  • Fundamental
  • Price
  • NAMS $23.33
  • NSP $79.66
  • Analyst Decision
  • NAMS Strong Buy
  • NSP Hold
  • Analyst Count
  • NAMS 7
  • NSP 4
  • Target Price
  • NAMS $38.17
  • NSP $95.67
  • AVG Volume (30 Days)
  • NAMS 538.3K
  • NSP 391.8K
  • Earning Date
  • NAMS 02-06-2025
  • NSP 02-06-2025
  • Dividend Yield
  • NAMS N/A
  • NSP 2.99%
  • EPS Growth
  • NAMS N/A
  • NSP N/A
  • EPS
  • NAMS N/A
  • NSP 3.16
  • Revenue
  • NAMS $33,594,000.00
  • NSP $6,547,871,000.00
  • Revenue This Year
  • NAMS $131.53
  • NSP $2.24
  • Revenue Next Year
  • NAMS N/A
  • NSP $5.31
  • P/E Ratio
  • NAMS N/A
  • NSP $25.40
  • Revenue Growth
  • NAMS 78.77
  • NSP 2.38
  • 52 Week Low
  • NAMS $15.19
  • NSP $71.69
  • 52 Week High
  • NAMS $27.29
  • NSP $117.48
  • Technical
  • Relative Strength Index (RSI)
  • NAMS 44.28
  • NSP 55.97
  • Support Level
  • NAMS $23.17
  • NSP $76.60
  • Resistance Level
  • NAMS $26.71
  • NSP $80.89
  • Average True Range (ATR)
  • NAMS 0.94
  • NSP 2.44
  • MACD
  • NAMS -0.40
  • NSP 0.49
  • Stochastic Oscillator
  • NAMS 23.65
  • NSP 90.33

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

Share on Social Networks: